Presentation (CTI)

OBJECTIVES: As healthcare systems continue to grapple with challenges to access, appropriate use and affordability of prescription drugs, monitoring and evaluation (M&E) frameworks can play an important role in informing policy decisions. Canada’s Drug Agency (CDA-AMC) convened and collaborated with partners in data and analytics to create a M&E framework that can be adapted and implemented to assess whether or not policy initiatives achieve intended outcomes by evaluating the changes in utilization, cost, health outcomes, and health system resources. Collaborative efforts are underway for the first application of this Framework through two pilot cases related to the universal coverage of diabetes and contraception medication and related products.
METHODS: M&E plans have been co-designed with key partners in data and analytics, identifying a set of core analytical questions grounded in top policy issues and related equity-informed metrics and indicators, and generating preliminary benchmark results. The analytical and technical aspects of these plans are further refined through external engagement with federal, provincial and territorial policy decision-makers, clinical and non-clinical experts and ongoing feedback and revision with project partners.
RESULTS: Through its convenorship function, the CDA-AMC can effectively bring together key partners and leverage their expertise and capacity to provide timely and consolidated analytical responses and data system solutions to top policy questions. These collaborative efforts are necessarily iterative, and CDA-AMC is employing multi-pronged engagement approaches to ensure the outcome of these collective efforts results in fit-for-purpose and actionable analytical insight.
CONCLUSIONS: This initiative demonstrates the potential for collaborative partnerships to enable analytics and identifying system-wide solutions to some of our most urgent health system needs.